Skip to main content

Geospiza, NuGen to Co-market Next-gen Sequencing Workflow Products

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Geospiza announced today a co-marketing deal with NuGen Technologies for the development of a next-generation sequencing workflow to accelerate discoveries for large disease research studies.

Financial and other terms of the deal were not disclosed.

Based in Seattle, Geospiza develops software for genetic analysis. NuGen, based in San Carlos, Calif., develops amplification and labeling systems for genomic research.

A spokeswoman for NuGen told GenomeWeb Daily News that the company will be providing library sample preparation technology to the collaboration.

"Combining our GeneSifter preconfigured lab and analysis cloud software with NuGen's Ovation and Encore reagents enables researchers to follow and document a step-by-step best practice for sample preparation combined with fully integrated data analysis and other sample information in one system," Rob Arnold, president of Geospiza, said in a statement.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.